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Received March 11, 2013; accepted June 19, 2013AbstractBackground: NAD(P)H:quinine oxidoreductase (NQO1) plays an important role in the metabolism of several carcinogens contained in ciga-
rettes. Inducible nitric oxide synthase (iNOS) expression had been detected in urinary bladder tumors. The aim of this study was to investigate
the interaction of iNOS and NQO1 on bladder cancer (BC) risk stratified by cigarette smoking status.
Methods: A total of 159 BC patients and 150 cancer-free controls were recruited from December 2003 to November 2004. Genotyping of NQO1
rs1800566 polymorphism and iNOS (CCTTT)n pentanucleotide repeat polymorphism was determined using the polymerase chain reaction-
restricted fragment length polymorphism and sequencing method. The odds ratio and 95% confidence interval (CI) were calculated as a
measure of the joint effect of NQO1 rs1800566 and iNOS (CCTTT)n polymorphisms on BC risk among cigarette smokers.
Results: Compared with study participants carrying the C/C genotype of NQO1 gene, those with C/T and T/T genotypes had a significantly
increased BC risk of 1.8 (95% CI ¼ 1.1e2.9). Among cigarette smokers, those who carried the 12-repeat allele of iNOS (CCTTT)n poly-
morphism had a significantly increased BC risk of 2.7 (95% CI ¼ 1.0e6.7). Furthermore, a significant combined effect of the C/T and T/T
genotypes of NQO1gene and the 12-repeat allele of iNOS (CCTTT)n repeat polymorphism on BC was found among cigarette smokers (odds
ratio ¼ 4.4, 95% CI ¼ 1.3e14.9).
Conclusion: Our findings suggest that a significant combined effect of NQO1 C/T and T/T genotypes and the 12-repeat allele of iNOS (CCTTT)n
polymorphism on BC exists, especially in those with the habit of cigarette smoking.
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According to the annual report of the Taiwan Cancer
Registry in 2012, the age-standardized incidence per 100,000
person-years of bladder cancer (BC) was 9.42 in males and
3.66 in females.1 BC is the second most common malignancy
of the genitourinary tract worldwide. Cigarette smoking is the
major risk factor for BC, resulting in a 2e4-fold risk amonghinese Medical Association. All rights reserved.
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erocyclic aromatic amines, and N-nitroso compounds con-
tained in cigarettes are thought to be the carcinogenic
constituents that result in the development of BC.4,5 Several
chemical carcinogens contained in cigarettes were metabo-
lized with phase II enzymes and then excreted in urine, but
certain components were activated into unstable reactive ox-
ygen species (ROS) and free radicals, leading to DNA
damage.6
NAD(P)H:quinine oxidoreductase (NQO1) is a key phase II
enzyme that plays an important role in protecting cells against
chemically induced oxidative stress and carcinogenicity.7 In
addition, NQO1 can metabolize some chemical carcinogens
such as benzo[a]pyrene-3,6-quinone, one of the carcinogenic
polycyclic aromatic hydrocarbons identified in cigarettes.8 The
enzyme activity may be influenced by certain functional poly-
morphisms located on the NQO1 gene. A common poly-
morphism (rs1800566) of NQO1 causes a nucleotide C-to-T
transition at nucleotide 609 of exon 6 and codes for a proline
(Pro)-to-serine (Ser) amino acid substitution.9,10 Previous
studies have indicated that NQO1 expression is higher in
bladder tumors, suggesting that NQO1 plays a key role in BC.11
The overexpression of inducible nitric oxide synthase
(iNOS) has been reported in several human cancers, including
BC.12,13 iNOS can increase the nitric oxide (NO) production in
response to various stimulations.14,15 It has been reported that
NO production is involved in the association between in-
flammatory response and BC.16 Several polymorphisms in the
promoter region of the iNOS gene have been shown to affect
its gene expression.17,18 A highly polymorphic (CCTTT)n
pentanucleotide repeat within the 50-putative promoter region
has been elucidated to modulate the expression of iNOS.19,20
Therefore, we conducted a hospital-based caseecontrol
study to investigate the combined effect of NQO1 rs1800566
(C609T) polymorphism and iNOS (CCTTT)n pentanucleotide
repeat polymorphism on the development of BC, especially
among cigarette smokers in Taiwan.
2. Methods2.1. Study populationFig. 1. Polymerase chain reaction products were digested with restriction
enzyme HinfI and analyzed by 2% agarose gel. Lane 1, 100-bp DNA ladder
(MBI Fermentas); Lanes 2 and 3, C/C genotype (271 bp); Lanes 4 and 5, C/T
genotype (271 bp, 151 bp, and 120 bp), and Lanes 6 and 7, T/T genotype
(151 bp and 120 bp).This study consisted of 309 participants enrolled from the
Department of Urology, Shin-Kong Wu Ho-Su Memorial
Hospital (Taipei, Taiwan) between April 2010 and June 2011.
A total of 159 cases with BC (mean age, 63.9  11.4 years)
were diagnosed with histopathological confirmation. This was
performed by board-certified pathologists using routine uro-
logical examinations. A total of 150 cancer-free controls
(mean age, 62.0  10.6 years) were recruited from a hospital-
based pool, including those who received a general health
examination at the Shin-Kong Wu Ho-Su Memorial Hospital.
All participants provided informed consent prior to being
interviewed and donating biospecimen. The Research Ethics
Committee of the Shin-Kong Wu Ho-Su Memorial Hospital
approved this study, and the study also complied with the
World Medical Association Declaration of Helsinki.2.2. Questionnaire interview and biospecimen collectionDemographic characteristics and lifestyle information such
as cigarette smoking were collected by interviewers using a
structured questionnaire. A 6e8-mL sample of vein blood was
drawn from each participant for genotype determination.2.3. Genotyping of NQO1 rs1800566 (C609T)
polymorphismGenomic DNA was extracted from the buffy coat of pe-
ripheral blood using the proteinase K digestion and phenol/
chloroform method and then stored at 80C. Genotyping was
determined using a polymerase chain reaction-restriction frag-
ment length polymorphism method. Briefly, the following se-
quences of the primer sets were designed for the NQO1 C609T
polymorphism: 50-AAGCCCAGAC CAACTTCT-30 (sense)
and 50-TCTCCTCATCCTGTACCTCT-30 (antisense). The po-
lymerase chain reaction conditions were as follows: one cycle at
95C for 5 minutes; 35 cycles of 95C for 30 seconds, 58C for
30 seconds, and 72C for 45 seconds, and a final extension at
72C for 7 minutes. After the digestion with the restriction
enzyme HinfI (New England Biolabs), the DNA fragments that
represented the NQO1 C609T polymorphism were determined
(C/C: 271 bp; C/T: 271, 151, and 120 bp and T/T: 151 and
120 bp; Fig. 1). To ensure quality, a random 10% of samples
were genotyped twice.2.4. Determination of iNOS (CCTTT)n pentanucleotide
repeat polymorphismThe following sequence of the primer sets were designed for
the iNOS (CCTTT)n pentanucleotide repeat polymorphism:
50-ACCCCTGGAAGCCTACAACTGCAT-30 (sense); 50-GCC
CTGCACCCTAGCCTGTCTCA-30 (antisense). The sense
primer was labeled with FAM dye. The thermal cycling was
performedwith an initial step at 94C for 5minutes, 30 cycles of
denaturation at 94C for 1 minute, annealing at 50C for 1
Table 2
Distribution of NQO1 C609T polymorphism among BC cases and controls.
Variable BC cases Controls OR (95% CI)
N (%) N (%)
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at 72C for 5 minutes. Genotyping was performed using an
internal size standard by ABI PRISM 310 genetic analyzer
(Applied Biosystems, Foster City, CA, USA).NQO1 C609T polymorphism
C/C 36 (22.6) 51 (34.0) 1.0a,b2.5. Statistical analysis
C/T 83 (52.2) 67 (44.7) 1.7 (1.0e3.0)*
T/T 40 (25.2) 32 (21.3) 1.8 (1.0e3.4)*
C/C 36 (22.6) 51 (34.0) 1.0a,b
C/T þ T/T 123 (77.4) 99 (66.0) 1.8 (1.1e2.9)*
Alleles
C 155 (48.7) 169 (56.3) 1.0a,b
T 163 (51.3) 131 (43.7) 1.4 (1.1e1.9)*
Ever smokers
C/C 21 (24.1) 18 (36.0) 1.0b,c
C/T 44 (50.6) 21 (42.0) 1.8 (0.8e4.1)
T/T 22 (25.3) 11 (22.0) 1.7 (0.7e4.6)
C/C 21 (24.1) 18 (36.0) 1.0b,c
C/T þ T/T 66 (75.9) 32 (64.0) 1.8 (0.8e3.8)
Alleles
C 86 (49.4) 57 (57.0) 1.0a,b
T 88 (50.6) 43 (43.0) 1.4 (0.9e2.7)
Never smokers
C/C 15 (20.8) 33 (33.0) 1.0b,c
C/T 39 (54.2) 46 (46.0) 1.8 (0.8e3.8)
T/T 18 (25.0) 21 (21.0) 1.8 (0.7e4.5)
C/C 15 (20.8) 33 (33.0) 1.0b,c
C/T þ T/T 57 (79.2) 67 (67.0) 1.8 (0.9e3.7)
Alleles
C 69 (47.9) 112 (56.0) 1.0a,b
T 75 (52.1) 88 (44.0) 1.4 (0.9e2.3)
*p < 0.05. BC ¼ bladder cancer; CI ¼ confidence interval.
a Multivariate logistic regression adjusted for age, sex and cigarette
smoking.
b OR ¼ odds ratio.
c Multivariate logistic regression adjusted for age and sex.A goodness-of-fit Chi-square test was used to examine the
HardyeWeinberg equilibrium (HWE) among controls. Ac-
cording to previous studies and the definition of the United
States Centers for Disease Control, study participants who
consumed more than 100 cigarettes during their lifetime were
defined as ever smokers, whereas those who consumed less
than 100 cigarettes in their lifetime were defined as never
smokers.21e23 The combined effects of NQO1 rs1800566
(C609T) polymorphism and iNOS (CCTTT)n pentanucleotide
repeat polymorphism on BC risk were estimated by odds ratios
(ORs) and its 95% confidence intervals (CIs) using a
multivariate-adjusted logistic regression model. All analyses
were performed using SAS for Windows, version 9.1 (SAS
Institute, Cary, NC, USA). A p value <0.05 was considered
statistically significant.
3. Results
No significant differences were observed in the distribution
of age, sex, and ethnicity between BC cases and cancer-free
controls (Table 1). The frequency of ever smokers among
BC cases (54.7%) was significant higher than that in controls
(33.3%). The genotype frequency of the NQO1 C609T poly-
morphism in controls was in HWE (c2 ¼ 0.98, p ¼ 0.52). In
Table 2, study participants who carried NQO1 C/T and T/T
genotypes had a significantly increased BC risk of 1.8 (95%
CI ¼ 1.1e2.9) compared to those with the C/C genotype. In
addition, individuals who carried the T allele also had a sig-
nificant increased BC risk of 1.4 (95% CI ¼ 1.1e1.9)
compared to those with the C allele.
The distribution of iNOS (CCTTT)n pentanucleotide repeat
polymorphism is shown in Table 3. We observed four repeatsTable 1
Distribution of selected characteristics of 159 bladder cancer cases and 150
controls.
Variable BC cases Controls pa
N (%) N (%)
Age (y) 0.08
<55 34 (21.4) 45 (30.0)
55 125 (78.6) 105 (70.0)
Mean  SD 63.9  11.4 62.0  10.6 0.13
Male 107 (67.3) 111 (74.0) 0.19
Female 52 (32.7) 39 (26.0)
Taiwanese 151 (95.0) 139 (92.7) 0.39
Others 8 (5.0) 11 (7.3)
Cigarette smoking
Never 72 (45.3) 100 (66.7) <0.001
Ever 87 (54.7) 50 (33.3)
BC ¼ bladder cancer; SD ¼ standard deviation.
a Independent t test and c2 test.(10, 11, 12, and 13) with a higher frequency (>10%) among
BC cases and controls. Based on the 25th percentile of the
distribution of iNOS (CCTTT)n pentanucleotide repeat poly-
morphism among controls, a repeat number 10 was regarded
as short repeats (S), whereas a repeat number 11 was
regarded as long repeats (L) in Table 4. Then, study partici-
pants were classified into three genotypes: S/S, S/L, or L/L.
Compared to participants with the iNOS S/S genotype, those
who carried the S/L and L/L genotypes had a nonsignificantly
increased BC risk. Among ever smokers, those who carried the
12-repeat allele of the iNOS gene had a significantly increased
BC risk (OR ¼ 2.7, 95% CI ¼ 1.0e6.7).
The combined effects of NQO1 C609T and iNOS (CCTTT)
n polymorphisms on BC risk are shown in Table 5. After
adjustment for age, sex, and cigarette smoking, participants
who carried both the NQO1 C/T and T/T genotypes and the
12-repeat allele of iNOS gene had a significantly increased BC
risk of 2.1 (95% CI ¼ 1.0e4.2) compared with those who
carried both the NQO1 C/C genotype and non-12-repeat allele
of iNOS gene. After stratification by cigarette smoking status,
the highest significant combined effect of the NQO1 C/T and
Table 3











166 6 1 (0.3) 1 (0.3)
171 7 1 (0.3) 0 (0.0)
176 8 0 (0.0) 0 (0.0)
181 9 12 (3.8) 9 (3.0)
186 10 69 (22.0) 63 (21.0)
191 11 61 (19.4) 50 (16.7)
196 12 53 (16.9) 48 (16.0)
201 13 35 (11.2) 41 (13.7)
206 14 26 (8.3) 24 (8.0)
211 15 24 (7.7) 21 (7.0)
216 16 12 (3.8) 25 (8.3)
221 17 11 (3.5) 13 (4.3)
226 18 6 (1.9) 3 (1.0)
BC ¼ bladder cancer.
a Lack of two BC cases with iNOS (CCTTT)n pentanucleotide repeat
polymorphism data.
Table 4




Overall Ever smokers Never smokers
OR (95% CI)b,c OR (95% CI)c,d OR (95% CI)c,d
S/S 1.0 1.0 1.0
S/L 1.5 (0.6e3.7) 1.5 (0.4e5.6) 1.4 (0.3e6.3)
L/L 1.1 (0.5e2.7) 1.1 (0.3e3.4) 1.7 (0.4e7.2)
S/S 1.0 1.0 1.0
S/L þ L/L 1.2 (0.5e2.9) 1.2 (0.3e3.9) 1.6 (0.4e6.6)
Other alleles 1.0 1.0 1.0
12-carriers 1.2 (0.7e1.9) 2.7 (1.0e6.7)* 1.0 (0.5e2.0)
*p < 0.05. CI ¼ confidence interval.
a S, repeat number 10; L, repeat number 11.
b Multivariate logistic regression adjusted for age, sex, and cigarette
smoking.
c OR ¼ odds ratio.
d Multivariate logistic regression adjusted for age and sex.
Table 5




repeat numbera OR (95% CI
C/C 12-carriers   
C/T+T/T non-12 carriers 
C/C non-12-carriers 1.0
1.7 (0.9-3.
C/T+T/T 12-carriers 2.1 (1.0-4.
  Ptrend = 0.0
a
 non-12-carriers = subjects without the (CCTTT
 (CCTTT)12 allele. 
b
 Multivariate logistic regression adjusted for age
c
 Multivariate logistic regression adjusted for age
d
 OR = odds ratio; CI = confidence interval. 
e P value for trend test. 
* p < 0.05. 
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BC was observed among ever smokers (OR ¼ 4.4, 95%
CI ¼ 1.3e14.9).4. Discussion
BC is a multifactorial malignancy in the urinary tract sys-
tem. Cigarette smoking and hazardous occupational exposure
have been reported to be major risk factors for BC.24,25
Chronic exposure to chemical carcinogens contained in ciga-
rettes will form DNA adducts and contribute to the develop-
ment of various cancers, including BC.6 In the present study,
we observed that BC cases had a significantly higher fre-
quency of cigarette smoking than controls, which was
consistent with previous studies.26,27
Carcinogens contained in cigarettes usually require detox-
ification by phase II enzymes, leading to less toxic and more
readily excreted derivatives. Therefore, the deficiency in
detoxification-related enzymes cannot only cause DNA dam-
age but also increase the accumulation of mutations.28 Genetic
polymorphisms of detoxification-related enzymes have been
shown to modulate the susceptibility to various malig-
nancies.29 The NQO1 enzyme is a phase II enzyme and plays a
role in the detoxification of toxic substances generated from
cigarette smoking.30 In our study, significantly increased BC
risk was found for participants who carried the C/T and T/T
genotypes of the NQO1 gene, which was consistent with
previous studies.31,32 Because the variant T allele of NQO1 C
609T polymorphism may decrease the enzyme activity in
catalyzing the chemical carcinogens,7 participants who carried
the C/T and T/T genotypes of the NQO1 gene were thought to
be more susceptible to the development of cigarette smoking-
related malignancies.
Because NO production has been reported to be involved in
the development of BC,16,33 we evaluated the effect of the
iNOS (CCTTT)n repeat polymorphism on BC in a Taiwanese
population. The distribution pattern of (CCTTT)n repeat
numbers in the present study was similar to that reported ins on BC risk stratified by cigarette smoking status.
Ever smokers Never smokers 
)b,d  OR (95% CI)c,d OR (95% CI)c,d
1.0 1.0 
1) 2.1 (0.9-5.0) 1.5 (0.6-3.7) 
2)*   4.4 (1.3-14.9)*   1.8 (0.6-5.0) 
5e   Ptrend = 0.02e   Ptrend = 0.27e
)12 allele; 12-carriers = those with the  
, sex and cigarette smoking. 
 and sex. 
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participants carrying the S/L and L/L genotypes of the iNOS
gene had a nonsignificantly increased BC risk; however, those
who carried the 12-repeat allele of the iNOS gene had a
significantly increased BC risk among ever smokers. The
(CCTTT)n repeat polymorphism, being located upstream of
the transcription start site, may affect the susceptibility to
various cancers through regulating the iNOS expression.17,18
In addition, the 12-repeat allele has been found to be associ-
ated with various diseases such as colorectal cancer.34 More-
over, the distribution frequency of the 12-repeat allele was
different between the Chinese population and the Caucasian
population.35 Although the function of the 12-repeat allele has
not been elucidated, we speculate that the iNOS 12-repeat
allele could have its own effect on BC or may have to
interact with functional polymorphisms located in other
candidate genes. According to the combination analysis in the
present study, a highest significant combined effect of the
NQO1 C/T and T/T genotypes and the 12-repeat allele of the
iNOS gene on BC was found among ever smokers. Therefore,
our findings implied that the geneegene interaction between
the NQO1 C609T polymorphism and iNOS (CCTTT)n repeat
polymorphism was predominant among cigarette smokers.
Our study has several limitations. First, we had no detailed
information about the participants’ cigarette smoking habits,
such as the number of cigarettes smoked per day and the
number of years smoked, for investigating the association
between the cumulative dosage of cigarette smoking and
NQO1 C609T polymorphism and iNOS (CCTTT) repeat
polymorphism. Second, clinical information regarding tumor
stage and grade were not collected in this study; therefore, we
could not examine the association between the tumor stage/
grade and NQO1 C609T polymorphism and iNOS (CCTTT)
repeat polymorphism. Third, we investigated only two poly-
morphisms located at NOQ1 and iNOS genes, respectively,
which incompletely represent the entire function of these two
genes. More functional polymorphisms should be included to
validate our results in a study with a larger sample size.
Therefore, the findings of our analyses must be interpreted
with caution.
In conclusion, our findings suggest there is a significant
combined effect of NQO1 C/T and T/T genotypes and the 12-
repeat allele of iNOS (CCTTT)n polymorphism on the
development of BC, especially among cigarette smokers in
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